Ranbaxy shares dip 35% on import warning

<p>Shares in Ranbaxy have fallen to a record low after an import alert from US authorities.</p>

Shares in Ranbaxy – the biggest drugmaker in India – have fallen to record lows today (September 15th), after an import alert issued by US authorities.

The warning from the US Food and Drug Administration (FDA) allows regulators to detain medications on the list "without physical sampling and analysis".

As a result of the alert, Ranbaxy shares dropped by as much as 35 per cent to their lowest since its original listing in 1991.

The FDA issued an alert from products manufactured at the company's Mohali plant on Friday.

According to the regulator, it can issue a warning when a firm does not conform with "current good manufacturing practices".

Its decision comes just months after Ranbaxy agreed to pay a record $500 million (£313 million) in fines over drug safety charges in the US.

Ranbaxy was downgraded to "underweight" from "overweight" by HSBC after the alert. The company has faced problems in the US over the past few years.

Build your confidence risk free
Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.